Literature DB >> 22301083

Physicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations.

Hannah K Knudsen1, Carrie B Oser, Amanda J Abraham, Paul M Roman.   

Abstract

The employment of physicians by substance abuse treatment organizations is understudied, despite physicians' importance in implementing pharmacotherapy and integrating treatment into the broader system of medical care. Drawing on data collected from 249 publicly funded treatment organizations, this study examined organizational and environmental factors associated with the employment of physicians in these settings. A negative binomial regression model indicated that greater numbers of physicians were employed when organizations offered detoxification services, were embedded in health care settings, and were larger in size. Funding barriers, including the costs of physicians and inadequate reimbursement by funders, were negatively associated with physician employment. Programs unaware that they could use state contract funding to pay for medical staff employed fewer numbers of physicians than programs aware of this type of state policy. Attempts to increase physician employment in substance abuse treatment may require attention to both organizational and environmental factors rather than simply trying to attract individuals to the field. Increasing physician employment may be challenging in the current economic climate.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22301083      PMCID: PMC3345304          DOI: 10.1016/j.jsat.2011.12.003

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  32 in total

1.  The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.

Authors:  Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2010-02-01

2.  Health reform and the scope of benefits for mental health and substance use disorder services.

Authors:  Rachel L Garfield; Judith R Lave; Julie M Donohue
Journal:  Psychiatr Serv       Date:  2010-11       Impact factor: 3.084

3.  Primary medical care and reductions in addiction severity: a prospective cohort study.

Authors:  Richard Saitz; Nicholas J Horton; Mary Jo Larson; Michael Winter; Jeffrey H Samet
Journal:  Addiction       Date:  2005-01       Impact factor: 6.526

4.  Racial and ethnic disparities in SSRI availability in substance abuse treatment.

Authors:  Hannah K Knudsen; Lori J Ducharme; Paul M Roman
Journal:  Psychiatr Serv       Date:  2007-01       Impact factor: 3.084

5.  The role of medical conditions and primary care services in 5-year substance use outcomes among chemical dependency treatment patients.

Authors:  Jennifer R Mertens; Alan J Flisher; Derek D Satre; Constance M Weisner
Journal:  Drug Alcohol Depend       Date:  2008-06-20       Impact factor: 4.492

6.  The role of state mental health authorities in managing change for the implementation of evidence-based practices.

Authors:  Kimberley Roussin Isett; M Audrey Burnam; Brenda Coleman-Beattie; Pamela S Hyde; Joseph P Morrissey; Jennifer L Magnabosco; Charles Rapp; Vijay Ganju; Howard H Goldman
Journal:  Community Ment Health J       Date:  2007-10-09

7.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

8.  Provision of on-site medical care to patients with hepatitis C in drug treatment units.

Authors:  Zdravko P Vassilev; Shiela M Strauss; Janetta M Astone; Peter D Friedmann; Don C Des Jarlais
Journal:  J Health Care Poor Underserved       Date:  2004-11

9.  Effect of primary medical care on addiction and medical severity in substance abuse treatment programs.

Authors:  Peter D Friedmann; Zhiwei Zhang; James Hendrickson; Michael D Stein; Dean R Gerstein
Journal:  J Gen Intern Med       Date:  2003-01       Impact factor: 5.128

10.  Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Hannah K Knudsen; Amanda J Abraham; J Aaron Johnson; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2009-07-03
View more
  5 in total

1.  Pharmacotherapy, Resource Needs, and Physician Recruitment Practices in Substance Use Disorder Treatment Programs.

Authors:  Hannah K Knudsen; Randy Brown; Nora Jacobson; Julie Horst; Jee-Seon Kim; Elizabeth Collier; Sanford Starr; Lynn M Madden; Eric Haram; Todd Molfenter
Journal:  J Addict Med       Date:  2019 Jan/Feb       Impact factor: 3.702

2.  Characteristics of drug demand reduction structures in Britain and Iran.

Authors:  Hooman Narenjiha; Roya Noori; Maziyar Ghiabi; Hamid-Reza Khoddami-Vishteh
Journal:  Epidemiol Biostat Public Health       Date:  2015

3.  The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis.

Authors:  Hannah K Knudsen
Journal:  J Stud Alcohol Drugs       Date:  2015-07       Impact factor: 2.582

4.  Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.

Authors:  Amanda J Abraham; Hannah K Knudsen; Traci Rieckmann; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2013-03       Impact factor: 2.582

5.  Longitudinal Examination of Medical Staff Utilization in Substance Use Disorder Treatment Organizations.

Authors:  Dail Fields; Paul Roman
Journal:  J Subst Abuse Treat       Date:  2015-07-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.